201 related articles for article (PubMed ID: 16332991)
1. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.
Schindler U; Strobel H; Schönafinger K; Linz W; Löhn M; Martorana PA; Rütten H; Schindler PW; Busch AE; Sohn M; Töpfer A; Pistorius A; Jannek C; Mülsch A
Mol Pharmacol; 2006 Apr; 69(4):1260-8. PubMed ID: 16332991
[TBL] [Abstract][Full Text] [Related]
2. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.
Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A
Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619
[TBL] [Abstract][Full Text] [Related]
3. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase.
Schrammel A; Behrends S; Schmidt K; Koesling D; Mayer B
Mol Pharmacol; 1996 Jul; 50(1):1-5. PubMed ID: 8700100
[TBL] [Abstract][Full Text] [Related]
5. The deactivation of soluble guanylyl cyclase by redox-active agents.
Dierks EA; Burstyn JN
Arch Biochem Biophys; 1998 Mar; 351(1):1-7. PubMed ID: 9500837
[TBL] [Abstract][Full Text] [Related]
6. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
7. Protoporphyrin IX generation from delta-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate cyclase activation.
Mingone CJ; Gupte SA; Chow JL; Ahmad M; Abraham NG; Wolin MS
Am J Physiol Lung Cell Mol Physiol; 2006 Sep; 291(3):L337-44. PubMed ID: 16899710
[TBL] [Abstract][Full Text] [Related]
8. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
9. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylyl cyclase activation promotes angiogenesis.
Pyriochou A; Beis D; Koika V; Potytarchou C; Papadimitriou E; Zhou Z; Papapetropoulos A
J Pharmacol Exp Ther; 2006 Nov; 319(2):663-71. PubMed ID: 16940434
[TBL] [Abstract][Full Text] [Related]
11. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
[TBL] [Abstract][Full Text] [Related]
13. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.
Martin E; Lee YC; Murad F
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12938-42. PubMed ID: 11687640
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
15. [Soluble platelet guanylate cyclase: significance of heme in regulating enzymatic activity and the role of the enzyme in platelet aggregation].
Severina IS
Biokhimiia; 1994 Mar; 59(3):325-39. PubMed ID: 7910045
[TBL] [Abstract][Full Text] [Related]
16. Identification of residues crucially involved in soluble guanylate cyclase activation.
Rothkegel C; Schmidt PM; Stoll F; Schröder H; Schmidt HH; Stasch JP
FEBS Lett; 2006 Jul; 580(17):4205-13. PubMed ID: 16831427
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
[TBL] [Abstract][Full Text] [Related]
18. Regeneration of the ferrous heme of soluble guanylate cyclase from the nitric oxide complex: acceleration by thiols and oxyhemoglobin.
Brandish PE; Buechler W; Marletta MA
Biochemistry; 1998 Dec; 37(48):16898-907. PubMed ID: 9836582
[TBL] [Abstract][Full Text] [Related]
19. Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat.
Kollau A; Opelt M; Wölkart G; Gorren ACF; Russwurm M; Koesling D; Mayer B; Schrammel A
Mol Pharmacol; 2018 Feb; 93(2):73-78. PubMed ID: 29138269
[TBL] [Abstract][Full Text] [Related]
20. Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation.
Holt AW; Martin DN; Shaver PR; Adderley SP; Stone JD; Joshi CN; Francisco JT; Lust RM; Weidner DA; Shewchuk BM; Tulis DA
Cell Signal; 2016 Sep; 28(9):1364-1379. PubMed ID: 27302407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
